Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7,473 Mln
P/E Ratio
17.64
P/B Ratio
20.54
Industry P/E
--
Debt to Equity
4.14
ROE
1.98 %
ROCE
25.72 %
Div. Yield
0 %
Book Value
2.82
EPS
3.44
CFO
$847.72 Mln
EBITDA
$944.38 Mln
Net Profit
$722.29 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Halozyme Therapeutics (HALO)
| 26.69 | -6.06 | 8.43 | 57.04 | 12.99 | 21.03 | 14.40 |
|
BSE Sensex*
| 2.63 | 3.73 | 5.80 | 8.92 | 11.76 | 20.12 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Halozyme Therapeutics (HALO)
| 29.08 | -35.04 | 41.51 | -5.85 | 140.89 | 21.19 | -27.66 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human... hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California. Read more
President, CEO & Director
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
President, CEO & Director
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Halozyme Therapeutics Inc (HALO) stood at $ 2,063 Mln as on 31-Dec-24
The share price of Halozyme Therapeutics Inc (HALO) is $60.57 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Halozyme Therapeutics Inc (HALO) has given a return of 12.99% in the last 3 years.
Halozyme Therapeutics Inc (HALO) has a market capitalisation of $ 7,473 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Halozyme Therapeutics Inc (HALO) is 17.64 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Halozyme Therapeutics Inc (HALO) and enter the required number of quantities and click on buy to purchase the shares of Halozyme Therapeutics Inc (HALO).
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
The CEO & director of Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.. is Halozyme Therapeutics Inc (HALO), and CFO & Sr. VP is Dr. Helen I. Torley M.B. Ch. B., M.R.C.P..
There is no promoter pledging in Halozyme Therapeutics Inc (HALO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Halozyme Therapeutics Inc. (HALO) | Ratios |
|---|---|
|
Return on equity(%)
|
198.42
|
|
Operating margin(%)
|
56.65
|
|
Net Margin(%)
|
43.74
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Halozyme Therapeutics Inc (HALO) was $0 Mln.
$0.08
(
